scholarly journals Further Steps in the Development of Pharmacoeconomics, Outcomes Research, and Health Technology Assessment in Central and Eastern Europe, Western Asia, and Africa

2013 ◽  
Vol 2 (2) ◽  
pp. 169-170 ◽  
Author(s):  
Imre Boncz ◽  
Zoltán Kaló ◽  
Mohamed Izham B. Mohamed Ibrahim ◽  
Dan Greenberg
Keyword(s):  
Health Technology Assessment ◽  
Eastern Europe ◽  
Technology Assessment ◽  
Outcomes Research ◽  
Central And Eastern Europe ◽  
Health Technology ◽  
Western Asia

scholarly journals Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Krzysztof Piotr Malinowski ◽  
Paweł Kawalec ◽  
Wojciech Trąbka ◽  
Christoph Sowada ◽  
Guenka Petrova ◽  
...  
Keyword(s):  
Health Technology Assessment ◽  
Eastern Europe ◽  
Technology Assessment ◽  
Central And Eastern Europe ◽  
Health Technology ◽  
Orphan Drugs ◽  
Gdp Per Capita ◽  
Public Budget ◽  
Per Capita ◽  
The Impact

Abstract Background The reimbursement of orphan drugs (OD) is an increasingly important for country policymakers, and still insufficiently understood, especially in Central and Eastern Europe. The aim of this research was to provide a comprehensive description of country-specific health technology assessment (HTA) policies as well as evaluate the percentage of HTA recommendations and reimbursement decisions for oncology OD. In addition, the study was designed to elucidate the impact of reimbursement of these drugs on the public budget and the agreement between HTA recommendations and reimbursement decisions in the analysed countries. A questionnaire survey was used to collect data on the reimbursement status, HTA recommendation, marketing authorisation, and public expenses on reimbursement in 2014, 2015, and 2016 for all oncology drugs with an orphan designation by the European Medicine Agency in 2017 in Bulgaria, Croatia, Czechia, Estonia, Hungary, Latvia, Lithuania, Poland, Romania, and Slovakia. The agreement between the HTA recommendation and reimbursement status was assessed using the kappa coefficient. The Pearson’s correlation was used to analyse the relationship between gross domestic product (GDP) and GDP per capita and reimbursement expenses. Results A total of 36 drugs were analysed (25% conditionally approved; 5.56% approved under exceptional circumstances). The share of reimbursed drugs ranged from 11.11% in Latvia to 41.67% in Poland. The highest share of positive recommendations was observed for Bulgaria and Estonia (36.11%), and the lowest, for Latvia (11.11%). The agreement varied from 0.4 for Poland to 1 for Latvia, Hungary, and Slovakia. Expenses were correlated with GDP (0.95 [0.81–0.99]), and not with GDP per capita (0.54 [− 0.136 to 0.873]). Expenses per capita were not correlated with GDP per capita (0.52 [− 0.15 to 0.87]). Conclusions In Hungary, Latvia, and Slovakia, a positive recommendation was associated with a reimbursement, and a negative one, with the lack of reimbursement. The reimbursement of oncology OD is associated with a growing burden for public budget, and the expenses are correlated with the total GDP. The highest share of drugs with any recommendation was observed in Poland, and the lowest, in Latvia and Romania. The share of reimbursed drugs was the lowest in Latvia and the highest in Poland.

scholarly journals Mapping capacity to conduct health technology assessment in Central, Eastern and South-Eastern Europe

2016 ◽  
Vol 57 (1) ◽  
pp. 66-70 ◽  
Author(s):  
Antonio Olry de Labry Lima ◽  
Leticia García Mochón ◽  
Araceli Caro Martínez ◽  
Eva Martín Ruiz ◽  
Jaime Espín Balbino
Keyword(s):  
Health Technology Assessment ◽  
Eastern Europe ◽  
Technology Assessment ◽  
Health Technology ◽  
South Eastern ◽  
South Eastern Europe ◽  
Central Eastern

Versorgungsforschung in der Klinischen Neuropsychologie – eine Standortbestimmung

2008 ◽  
Vol 19 (4) ◽  
pp. 253-269 ◽  
Author(s):  
Sabine Heel ◽  
Sonja Fischer ◽  
Stefan Fischer ◽  
Tobias Grässer ◽  
Ellen Hämmerling ◽  
...  
Keyword(s):  
Health Technology Assessment ◽  
Technology Assessment ◽  
Health Technology ◽  
Empirische Forschung

Zunächst führt dieser Artikel in die wesentlichen Begrifflichkeiten und Zielstellungen der Versorgungsforschung ein. Er befasst sich dann mit der Frage, wie die einzelnen Teildisziplinen der Versorgungsforschung, (1) die Bedarfsforschung, (2) die Inanspruchnahmeforschung, (3) die Organisationsforschung, (4) das Health Technology Assessment, (5) die Versorgungsökonomie, (6) die Qualitätsforschung und zuletzt (7) die Versorgungsepidemiologie konzeptionell zu fassen sind, und wie sie für neuropsychologische Anliegen ausformuliert werden müssen. In diesem Zusammenhang werden die in den einzelnen Bereichen jeweils vorliegenden versorgungsrelevanten Studienergebnisse referiert. Soweit es zulässig ist, werden Bedarfe für die Versorgungsforschung und Versorgungspraxis in der Neurorehabilitation daraus abgeleitet und Anregungen für die weitere empirische Forschung formuliert. Der Artikel bezieht sich – entsprechend seines Anliegens – ausschließlich auf Studien, die sich mit der Situation der deutschen Neurorehabilitation befassen.

Sign in / Sign up

Export Citation Format

Share Document